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Abstract In rat liver, a single serine:pyruvate/alanine:glyox-
ylate aminotransferase (SPT or SPT/AGT) gene is transcribed 
from two transcription initiation sites. Transcription from the 
upstream site generates the mRNA encoding the precursor for 
mitochondrial SPT (pSPTm) and is markedly enhanced by the 
administration of glucagon or cAMP. In this report we show the 
increase in the downstream transcript, the peroxisomal SPT 
(SPTp) mRNA, caused by peroxisome proliferators and 
triiodothyronine (T3). In the case of T 3 , the pSPTm mRNA 
was also increased 72 h after a single administration of the 
hormone in addition to an earlier increase in SPTp mRNA. 
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1. Introduction 
Serine:pyruvate aminotransferase (SPT; another name is 
alanine:glyoxylate aminotransferase, A G T ) is an enzyme 
whose subcellular localization in rat liver is mitochondrial 
and peroxisomal [1,2]. Two m R N A s encoding SPTs with dif-
ferent organelle distributions are generated from a single gene 
through alternative transcription initiation from two sites, 
only 65 nucleotides apart , in the same exon 1 [3]. Transcrip-
tion from the upstream site generates the mitochondrial SPT 
(SPTm) m R N A encoding the precursor for SPTm (pSPTm), 
which contains an N-terminal extension peptide of 22 amino 
acids as a mitochondrial targeting signal [3]. This upstream 
transcription is markedly and selectively enhanced by the ad-
ministration of glucagon to rats [4] or the addition of c A M P 
to the culture medium of primary hepatocytes [5], The tran-
scription from the downstream site, on the other hand, gen-
erates the peroxisomal SPT (SPTp) m R N A which encodes the 
mature size of the enzyme, and this transcription is affected by 
neither glucagon nor cAMP. Thus the rat SPT gene has the 
unique characteristic that two promoters, which are quite dif-
ferent in their response to glucagon or c A M P stimuli, are 
located very closely. Several studies have revealed the induc-
tion of SPTp by peroxisome proliferators through enzymatic 
or histochemical analysis [6-10], but detailed analysis at the 
m R N A level remains to be performed. We analyzed in this 
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study the induction of SPTp by peroxisome proliferators and 
triiodothyronine (T3) at the m R N A and/or protein levels. 
2. Materials and methods 
2.1. Animals and drug administration 
Male Wistar rats weighing 200-250 g were given daily intraperito-
neal injections of clofibrate (ethyl p-chlorophenoxyisobutyrate) at 
doses of 20 or 40 mg/100 g body weight for 7 days, or a daily intra-
gastric dose of di-(2-ethylhexyl)phthalate (DEHP) (0.25 g/100 g body 
weight) for 4 or 8 days. The rats were also given a single intraperito-
neal injection of T3 (50 ug/100 g body weight) 3, 6, 12, 24 or 72 h 
before they were killed, or a single intraperitoneal injection of gluca-
gon (0.3 mg/100 g body weight) 3.5 h before they were killed. 
2.2. Experimental procedures 
Subcellular fractionation of a clofibrate-administered rat liver ex-
tract on a sucrose density gradient was performed as reported previ-
ously [2]. Dot blot analysis was carried out using 'probe E' [3] of SPT 
cDNA and the Hinfl (1278)-PvwII (1702) fragment (424 bp) of rat 
serum albumin cDNA [11] as probes. For RNA blot analysis, 'probe 
A' [3] of SPT cDNA was also used as a specific probe for pSPTm 
mRNA. In vitro translation was performed as described previously 
[4], and the specific products were detected by use of rabbit anti-rat 
SPT serum and rabbit anti-rat serum albumin serum. Ribonuclease 
protection and primer extension analyses were carried out using 
'probe a' and 'an oligonucleotide of 17 bases', respectively, as re-
ported [3]. 
3. Results and discussion 
Peroxisome proliferators such as clofibrate [12] and D E H P 
[13] are known to increase peroxisomes and also to induce 
peroxisomal enzymes. Enzymes of the (3-oxidation system 
(acyl-CoA oxidase, etc.) are markedly induced by D E H P up 
to 30-fold, whereas the induction of catalase is only about 2-
fold [14]. Fig. 1 shows the effects of clofibrate on the activities 
of SPT in mitochondrial and peroxisomal fractions which 
were separated by sucrose density gradient centrifugation. 
Fig. 1A shows that SPT was detected in two subcellular or-
ganelles, peroxisomes and mitochondria, and the soluble frac-
tion as reported previously [1,2]. Clofibrate administration 
caused an increase in peroxisomes as shown by the catalase 
profile, and these peroxisomes also contained SPT (Fig. 
1B,C). F r o m the combined catalase activities in the particulate 
fractions 1-20, the induction ratios of catalase at doses of 20 
and 40 mg/100 g body weight of clofibrate were calculated to 
be 1.66-fold and 1.43-fold of the control level, respectively. 
Because the activity profile of SPTp is similar to that of cata-
lase, the induction ratio of SPTp was suggested to be 1.4-1.7-
fold of the control level after clofibrate treatment. These val-
ues for SPT induction are in good agreement with those in 
other reports [6-8,10]. On the other hand, the induction ratio 
of glutamate dehydrogenase, a marker enzyme of mitochon-
dria, was similarly calculated from the combined activities in 
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Fig. 1. Subcellular fractionation by sucrose density gradient centrifugation of liver extracts of rats treated with clofibrate. Rats were given daily 
intraperitoneal injections of clofibrate at doses of 20 (B) or 40 mg/100 g body weight (C) for 7 days. In control rats (A), only peanut oil, the 
solvent for clofibrate, was injected for 7 days. Livers were excised after 24 h fasting and then homogenized. Subcellular fractionation was car-
ried out as described in Section 2, and the activities of SPT, glutamate dehydrogenase (GDH), and catalase in each fraction were determined 
as reported previously [2]. The left and right sides of the figures correspond to the bottom and top of the gradient, respectively. 
fractions 1-20 to be 1.06-fold and 0.88-fold of the control 
level with 20 and 40 mg/100 g body weight of clofibrate ad-
ministered, respectively. SPTm shows a similar activity profile, 
indicating that clofibrate has no effect on the glutamate de-
hydrogenase and SPTm activities. These results indicate that 
SPTp and catalase belong to the same group of peroxisomal 
enzymes, which are induced moderately by clofibrate. 
In our preliminary experiment, the administration of 
DEHP, another peroxisome proliferator, also caused a small 
but significant increase in SPT activity. We then examined the 
effect of DEHP on the level of SPT mRNA. The effect of T3 
was also examined because several candidates for the half-site 
motif of the thyroid hormone-responsive element, AGGTCA, 
were observed in the 5'-flanking region of the SPT gene [15]. 
Fig. 2 shows the results of dot blot analysis. A cDNA frag-
ment of rat serum albumin was used for normalization as to 
the change in the induction of SPT mRNA. Various amounts 
of poly(A) RNA were dotted in triplicate, and then hybridized 
with the SPT and serum albumin probes, autoradiographed 
and quantitated by densitometric analysis (Fig. 2A,B). By us-
ing the values within the linear range, the induction of SPT 
mRNAs at various time points after the DEHP or T3 treat-
ment was calculated (presented in Fig. 2C). The results show 
that both DEHP and T3 induce SPT mRNA. 
To determine whether the effects of these reagents are spe-
cific for SPTp, RNA blot analysis and SDS-PAGE analysis of 
the immunoprecipitated in vitro translation product were car-
ried out (Fig. 3A,B). Both DEHP and T3 caused an increase 
in SPTp mRNA of 1700 nucleotides (Fig. 3A, SPT probe E), 
and the induction of SPTp of 43 kDa (Fig. 3B). However, 
pSPTm mRNA of 1900 nucleotides (Fig. 3A, lane 9) and 
pSPTm of 45 kDa (Fig. 3B, lane 9) were detected only 
when poly(A) RNA prepared 72 h after T3 treatment was 
used. This was confirmed by detecting the pSPTm mRNA 
signal of 1900 nucleotides using 'SPT probe A', which is spe-
cific for pSPTm mRNA (lower panel in Fig. 3A, lane 9). 
There were no significant changes in the amount of in vitro 
translated serum albumin. As the pSPTm mRNA and its 
translation product, pSPTm, seemed to be induced 72 h after 
T3 administration, we tried to confirm this by means of a 
ribonuclease protection assay (Fig. 3C) and primer extension 
analysis (Fig. 3D). Lane 9 in Fig. 3C shows that 72 h after T3 
treatment, transcription from the upstream site, generating 
pSPTm mRNA, was significantly enhanced. This was also 
confirmed by primer extension analysis, as shown in Fig. 
3D (lane 4). 
Two modes of action of T3 on SPT mRNA induction are 
suggested by the above results. One is an early effect, inducing 
SPTp mRNA, and the other is a delayed effect, inducing 
pSPTm mRNA. The early effect of T3 may be explained in 
part by the peroxisome proliferator-like action of T3, as it was 
shown in a previous report [16] that hyperthyroidism caused 
by T3 results in an increase in the peroxisome number in rat 
liver. It has been reported, concerning the delayed effect of T3, 
that thyroid hormones induce hyperinsulinemia in the rat [17], 
and that insulin, as well as glucagon, causes the induction of 
pSPTm mRNA [18]. 
The dual subcellular localization of SPT in rat liver is prob-
ably related to its specific physiological role in each organelle. 
SPTm may contribute to the gluconeogenesis from or catab-
olism of serine in mitochondria [19] while the role of SPTp is 
to reduce oxalate formation by the conversion of glyoxylate, 
an immediate precursor of oxalate, into glycine as manifested 
by the SPTp-deficient human disease, primary hyperoxaluria 
Fig. 2. Dot blot analysis of SPT mRNA after DEHP or T3 admin-
istration. Various amounts of poly(A) RNAs prepared from the liv-
ers of normal (N), DEHP-fed (DEHP), or T3-administered (T3) rats 
were spotted in triplicate onto nylon membranes, and then hybrid-
ized with 3 P-labeled SPT probe E (A) or albumin probe (B). A 
part of the results of several experiments is shown in (A) and (B). 
C: An autoradiogram of each dot was quantitated by densitometric 
analysis using an ATTO Densitograph AE-6900M. The extent of in-
duction of SPT mRNA after DEHP or T3 treatment was deter-
mined by normalizing the SPT mRNA signals with albumin signals, 
using values in the linear range of the densitometric data. 
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Fig. 3. RNA blot (A), in vitro translation (B), ribonuclease protec-
tion (C) and primer extension (D) analyses of SPT mRNA after 
DEHP or T3 treatment. A: Two types of SPT probes, E and A, 
were used for RNA blot analysis. Probe E is common to both 
pSPTm (1900 nt) and SPTp (1700 nt) mRNAs, whereas probe A is 
specific to pSPTm mRNA, as reported previously [3]. Poly(A) RNA 
prepared from the livers of rats injected with glucagon 3.5 h before 
they were killed (G3.5) was used as the glucagon-induced control, 
the major species of mRNA being pSPTm mRNA of 1900 nt, as re-
ported [18]. B: For in vitro translation analysis, an anti-SPT serum 
and an anti-serum albumin serum were used. C: The antisense 
probe used in this experiment was 'probe a', which was used for the 
detection of the difference in the 5'-end of SPT mRNA in the pre-
vious study [3]. 2 u.g of poly (A) RNA was used in each lane, except 
in lane 1, where 0.2 ug of the RNA was used because of the strong 
signal. D: Primer extension analysis was carried out as described 
Section 2 using 10 |a,g of poly(A) RNA prepared from the livers of 
normal rats (N), rats administered T3 for 72 h (T72), or rats in-
jected with glucagon 3.5 h before they were killed (G3.5). The 5'-
end-labeled Hinfl digest of pBR322 was applied in lane 1 as size 
markers: a (504 bp), b (396 bp), c (344 bp), d (298 bp), e (221/220 
bp), f (154 bp) and g (75 bp). 
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type 1 [20]. In rat liver, the level of mitochondrial and perox-
isomal SPT appears to be primarily determined by the tran-
scription from the upstream and downstream initiation sites, 
respectively, although the turnover rate of SPTm and SPTp 
may also contribute to the steady-state concentration of this 
268 
enzyme in each organelle. It is, therefore, necessary to analyze 
the transcriptional regulation of the SPT gene to understand 
the proper distribution of SPT to mitochondria and peroxi-
somes under various metabolic conditions. 
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